THERAPEUTIC PRODUCTS DIRECTORATE - ISSUES RELATED TO GMP GUIDELINES, COST RECOVERY REVIEWS.CONCERNS REGARDING DRUG WHOLESALERS WHO HAVE NOT APPLIED FOR AN ESTABLISHMENT LICENSE BUT CONTINUE TO OPERATE IN CANADA--WOULD LIKE TO SEE REQUIREMENT FOR PROVINCIAL REGISTRIES OF WHOLESALERS, WITH NOTIFICATION OF SAME TO FEDERAL TPD. WORKING WITH NAPRA AND PROVINCIAL REGULATORY BODIES TO ENSURE THAT PHARMACEUTICALS ARE SOLD IN APPROPRIATE RETAIL OUTLETS.WORKING WITH INDUSTRY CANADA TO MONITOR POTENTIAL SUPPLY DISRUPTIONS IN CANADA GIVEN TERRORIST ACTION IN US.WORKING WITH TPD "APETI" GROUP TO DEVELOP RECOMMENDED GUIDELINES FOR ELECTRONIC ORDERING OF CONTROLLED SUBSTANCES.PARTICIPATE IN ANNUAL ORGANIZATIONAL REVIEW WITH TPD.
Objets poursuivis : Renseignements prospectifs :
DEVELOP RECOMMENDATIONS FOR TPD RE: ELECTRONIC ORDERING OF CONTROLLED SUBSTANCES.PARTICIPATE IN INFORMATION WORKSHOP RE: NEW GMP GUIDELINE REVISIONS.PARTICIPATE IN MEDICAL DEVICES COST-RECOVERY REVIEW COMMITTEE AND BUSINESS IMPACT SUB-COMMITTEE.FOLLOW UP, COMMENT, POSSIBLY LOBBY ON ANY REGULATORY OR POLICY CHANGES FROM THERAPEUTIC PRODUCTS DIRECTORATE OR HEALTH OR INDUSTRY CANADA THAT IMPACT ON HEALTH CARE, PHARMACEUTICAL INDUSTRY, OR DISTRIBUTION OF PRODUCTS IN THE PHARMACY SUPPLY CHAIN; PARTICIPATE IN DISCUSSIONS ON NATIONAL PHARMACARE PROGRAM IF DIALOGUE DEVELOPS. RETAIN AN INTEREST IN REGULATORY FRAMEWOK FOR NATURAL HEALTH PRODUCTSALTHOUGH NOT AN AREA REQUIRING DIRECT INVOLVEMENT OF CWDA WATCHING WITH INTEREST THE ISSUE OF DIRECT-TO-CONSUMER ADVERTIZING OF PHARMACEUTICALS.